Dotmatics Launches Chemistry Solution for Small Molecule Drug Discovery
Summary
The solution combines Dotmatics’ enterprise scientific platform with workflows and best practices derived from the company’s 15+ years of experience supporting small molecule drug discovery. The Chemistry Solution for Small Molecule Drug Discovery promotes greater collaboration and productivity among research teams, reduces operational inefficiencies, and speeds the process of taking data from insights to decisions. “While small molecule science is making incredible progress in the market, the cost of the drug discoveries is higher than ever, burdened by complex workflows and fragmented data and analysis tools,” said Mike McKee, president of Dotmatics. Data in small molecule drug discovery is commonly siloed in proprietary systems forcing scientists to choose between compromising speed or accuracy. Dotmatics is backed by Insight Partners, a global venture capital and private equity firm investing in high-growth technology and software scaleup companies.
Classifications
AskAI Classifications
LabelsLinked Companies
